ClinicalTrials.gg
CompletedNCT00165659Updated Jan 29, 2010

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

A Phase 2 interventional study of DONEPEZIL HYDROCHLORIDE in Alzheimer Disease, sponsored by Eisai Limited. Completed at 65 sites in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2010-01-29.

Sponsored by Eisai Limited · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Started
2002
with 1 other
Phase 2
4 of 60
none open now
Registered
4th of 60
by date
Lead sponsor
2 of 60
Eisai Limited

Among the 60 studies testing donepezil in Alzheimer Disease, this one is one of 2 that started in 2002, is one of 4 in phase 2, and was the 4th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus* and SIB** as the primary efficacy measures. Safety of E2020 will also be evaluated.

(*for overall evalution of clinical symtoms) (**for cognitive function test)

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with diagnostics of Alzheimer's disease (AD) according to .
  • Patients with modified Hachinski Ischemic scale score of ≦6.
  • FAST score of ≧6 at baseline (4 weeks before starting study treatment).
  • score between 1 and 12 at baseline (4 weeks before starting study treatment).
  • Imaging diagnostics (CT, MRI, etc., within 24 months consistent with the diagnosis of AD without any other comorbid pathologies found. If a significant change in clinical status suggesting other types of dementia (except AD) is suspected between the final image diagnosis and the time of starting observation, the scan test should be repeated.
  • Patients who can comply with the requirements on concomitant drugs/therapies from the baseline phase or before.
  • Patients aged 50 years or older.
  • Outpatients. Even in the case of an outpatient or a patient attending on the outpatient-visit basis from a nursing home facility, the caregiver must be a constant and reliable informant with minimum of 3 days per week direct contact with the patient (for at least 4 hours per day on waking hours). This contact is necessary to ensure accurate reporting of the patient's behavior and his/her ability to perform ADLs.
  • Patients who are expected to complete all procedures scheduled during the Screening and Baseline visit and who have a reliable caregiver or family member who agrees to accompany the patient to all clinic visits, provide information about the patient as required by the protocol, and ensure compliance with the treatment schedule.
  • Patients who can swallow tablets without pulverization.
  • Patients who are ambulatory at least aided (walker) and have vision and hearing necessary for compliance with testing procedures (eyeglasses and/or hearing aid permissible).
  • Patients whose representatives can sign the written .

Exclusion criteria

Exclusion Criteria:

  • Patients with dementia other than AD.

    1. Patient whose imaging test shows "circumscribed cerebral lesion or multiple infarcts" which is suspected to be the responsible cause of dementia (mixed-type dementia)
    2. Patients with other types of dementia
  • Patients with a current diagnosis of major depressive disorder or any current serious psychiatric diagnosis othe than AD.
  • Patients without a reliable caregiver.
  • Patients who are expected to enter a nursing home facility within 6 months after starting study treatment (excluding a transient entry).
  • Patients with active or conditions affecting absorption, distribution or metabolism of study drugs (e.g., inflammatory bowel disease, gastric or duodenal ulcers, or severe lactose intolerance).
  • Patients with a known to a component of donepezil hydrochloride preparation or piperidine derivatives.
  • Patients complicated with a severe gastrointestinal, hepatic, renal, endocrine, or cardiovascular system disease (e.g., sick sinus syndrome, intraarterial and supraventricular conduction disorder, etc.).
  • Patients with a history of severe bronchial asthma or obstructive pulmonary disease.
  • Patients with a severe extrapyramidal disease (Parkinson's disease, Parkinson's syndrome, etc.).
  • Patients with diabetes mellitus with uncontrolled blood glucose levels (HbAlc of ≧10%).
  • Hypertension patients with uncontrolled blood pressure (diastolic blood pressure of ≧95 mmHg).
  • Patients with uncontrolled thyroid dysfunction.
  • Patients with a history of seizure or convulsion within the previous 3 months (obtaining ).
  • Patients with a known or suspected history of alcohoism or drug dependence within the recent 10 years.
  • Patients with malignant tumors.
  • Women of pregnant, possibly pregnant, or lactating.
  • Patients who have participated in another clinical study within the recent 3 months (before giving consent).
  • Any other patients who are judged to be ineligible for study entry by the investigator or subinvestigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Outcomes: Efficacy:

  2. CIBIC plus*, SIB**

  3. (*for overall evalution of clinical symtoms)

  4. (**for cognitive function test)

  5. Safety:

  6. Adverse event, adverse drug reaction, vital sign, clinical laboratory parameter, electrocardiogram

Secondary outcomes

  1. Efficacy

  2. Behave-AD, ADCS-ADL-sev

07

Study locations

65 sites
  • Chita, Aichi-prefecture 470-3411, Japan
  • Nagoya, Aichi-prefecture 466-0065, Japan
  • Toyohashi, Aichi-prefecture 441-8124, Japan
  • Akita, Akita-prefecture 010-0146, Japan
  • Akita, Akita-prefecture 010-0874, Japan
  • Daisen, Akita-prefecture 019-2413, Japan
  • Kashiwa, Chiba-prefecture 277-0004, Japan
  • Fukui, Fukui-prefecture 910-0046, Japan
  • Fukuoka, Fukuoka-prefecture 811-1122, Japan
  • Fukuoka, Fukuoka-prefecture 813-0025, Japan
  • Fukuoka, Fukuoka-prefecture 814-0133, Japan
  • Fukuoka, Fukuoka-prefecture 819-0165, Japan
  • Kita-kyusyu, Fukuoka-prefecture 802-0978, Japan
  • Fukushima, Fukushima-prefecture 960-1247, Japan
  • Koriyama, Fukushima-prefecture 963-1309, Japan
  • Fujioka, Gunma-prefecture 375-0017, Japan
  • Numata, Gunma-prefecture 378-0014, Japan
  • Hiroshima, Hiroshima-prefecture 730-0011, Japan
  • Hiroshima, Hiroshima-prefecture 734-0037, Japan
  • Otake, Hiroshima-prefecture 739-0651, Japan
  • Asahikawa, Hokkaido-prefecture 078-8208, Japan
  • Aio, Hyogo-prefecture 678-0081, Japan
  • Asago, Hyogo-prefecture 679-3423, Japan
  • Kako, Hyogo-prefecture 675-1114, Japan
  • Kobe, Hyogo-prefecture 650-0017, Japan
  • Kobe, Hyogo-prefecture 653-0013, Japan
  • Tsuchiura, Ibaraki-prefecture 300-0053, Japan
  • Tsukuba, Ibaraki-prefecture 305-0005, Japan
  • Kanazawa, Ishikawa-prefecture 920-0934, Japan
  • Kawasaki, Kanagawa-prefecture 211-0063, Japan
  • Kawasaki, Kanagawa-prefecture 216-0015, Japan
  • Sagamihara, Kanagawa-prefecture 228-0815, Japan
  • Kochi, Kochi-prefecture 780-0842, Japan
  • Kyoto, Kyoto-prefecture 600-8212, Japan
  • Kyoto, Kyoto-prefecture 607-8064, Japan
  • Nagasaki, Nagasaki-prefecture 850-0841, Japan
  • Nagasaki, Nagasaki-prefecture 852-8061, Japan
  • Sasebo, Nagasaki-prefecture 857-0022, Japan
  • Kashihara, Nara-prefecture 634-0813, Japan
  • Joetsu, Niigata-prefecture 949-3116, Japan
  • Kashiwazaki, Niigata-prefecture 945-1114, Japan
  • Tsukubo, Okayama-prefecture 701-0304, Japan
  • Moriguchi, Osaka-prefecture 570-0074, Japan
  • Neyagawa, Osaka-prefecture 572-0801, Japan
  • Osaka, Osaka-prefecture 540-0006, Japan
  • Osaka, Osaka-prefecture 545-0051, Japan
  • Osaka, Osaka-prefecture 558-0056, Japan
  • Suita, Osaka-prefecture 565-0874, Japan
  • Takatsuki, Osaka-prefecture 569-1041, Japan
  • Saitama, Saitama-prefecture 338-0003, Japan
  • Izumo, Shimane-prefecture 693-0021, Japan
  • Shizuoka, Shizuoka-prefecture 424-0911, Japan
  • Kawachi, Tochigi-prefecture 329-0431, Japan
  • Shimotsuga, Tochigi-prefecture 321-0207, Japan
  • Chiyoda-ku, Tokyo-prefecture 101-0024, Japan
  • Hachioji, Tokyo-prefecture 193-0944, Japan
  • Higashimurayama, Tokyo-prefecture 189-0002, Japan
  • Itabashi-ku, Tokyo-prefecture 173-0015, Japan
  • Kodaira, Tokyo-prefecture 187-0031, Japan
  • Machida, Tokyo-prefecture 194-0023, Japan
  • Shinjuku-ku, Tokyo-prefecture 160-0023, Japan
  • Nanto, Toyama-prefecture 939-1851, Japan
  • Gobo, Wakayama-prefecture 644-0002, Japan
  • Wakayama, Wakayama-prefecture 640-8435, Japan
  • Hofu, Yamaguchi-prefecture 747-0065, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002 and a primary completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 14, 2005
Start
Nov 2002
Primary completionActual
May 2005
Last update
Jan 29, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00165659
Lead sponsor
Eisai Limited
First posted
Sep 14, 2005
Start date
Nov 2002
Primary completion
May 2005
Last update
Jan 29, 2010

Study contacts

Itaru Arimoto
study director · Eisai Co., Ltd - Development Clinical Research Dept., Clinical Research Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion